Virtu Financial LLC Hepion Pharmaceuticals, Inc. Transaction History

Virtu Financial LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	BUY	$0.31 - $1.06 $10,024 - $34,276	32,336 Added 152.78%	53,501 $42,000
Q4 2022 Feb 15, 2023	SELL	$0.27 - $11.9 $12,591 - $554,980	-46,637 Reduced 68.78%	21,165 $6,000
Q3 2022 Nov 07, 2022	BUY	$0.51 - $10.4 $22,882 - $466,616	44,867 Added 195.63%	67,802 $34,000
Q2 2022 Aug 09, 2022	BUY	$0.57 - $1.22 $13,072 - $27,980	22,935 New	22,935 $13,000
Q1 2022 May 17, 2022	SELL	$0.93 - $1.29 $46,461 - $64,447	-49,959 Closed	0 $0
Q4 2021 Feb 17, 2022	BUY	$1.14 - $1.58 $56,953 - $78,935	49,959 New	49,959 $57,000
Q3 2021 Nov 12, 2021	SELL	$1.39 - $2.1 $158,277 - $239,124	-113,869 Closed	0 $0
Q2 2021 Sep 17, 2021	SELL	$1.56 - $2.26 $101,651 - $147,263	-65,161 Reduced 36.4%	113,869 $225,000
Q1 2021 May 19, 2021	BUY	$1.77 - $2.98 $316,883 - $533,509	179,030 New	179,030 $329,000
Q2 2020 Aug 07, 2020	SELL	$1.31 - $3.09 $19,310 - $45,549	-14,741 Closed	0 $0
Q4 2019 Feb 04, 2020	SELL	$2.25 - $6.99 $7,467 - $23,199	-3,319 Reduced 18.38%	14,741 $79,000
Q3 2019 Nov 20, 2019	BUY	$2.09 - $4.12 $37,745 - $74,407	18,060 New	18,060 $44,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $35.1M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.